Compare Organon & Co. Common Stock (OGN) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Wendys Co — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Wendys Co trades at $6.48 (market cap $1.21B). The key difference: Organon & Co. Common Stock is far larger — about 3× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.41%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Wendys Co for 78 Days on average.
| OGN | WEN | |
|---|---|---|
Market Cap | $3.62B | $1.21B |
Volume | 2,892,999 | 3,737,069 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $9.33 |
52-Week Low | $5.70 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $11.04B | $4.94B |
Dividend Yield | 0.58% | 4.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Wendy's stock trades at $6.44, up 2.06% today, but remains near multi-year lows amid ongoing operational challenges. The company shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, while maintaining consistent revenue around $2.2B. However, declining net income margins (5.72% in 2025) and a major franchisee bankruptcy highlight significant headwinds. Technical indicators show bearish momentum with the stock trading near key support levels.
While Wendy's valuation appears compelling, the stock faces substantial risks from declining profitability, high debt levels, and competitive pressures. Analyst consensus leans cautious with a $7.58 price target, suggesting limited upside. The recent CEO change and international expansion plans offer potential catalysts, but execution risks remain elevated given the challenging restaurant environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
